To B or not to B - That is the question for myocardial infarction

Nature Medicine

Volumn 19, Issue 10, 2013, Pages 1208-1210

  Kim, Nancy D ^a   Luster, Andrew D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD20 ANTIBODY; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR2; EOTAXIN 2; IMMUNOGLOBULIN M; INTERLEUKIN 18; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR;

ARTICLE; B LYMPHOCYTE; BONE MARROW; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART VENTRICLE REMODELING; HUMORAL IMMUNE DEFICIENCY; LEUKOCYTE MOTILITY; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; HEART; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; B-LYMPHOCYTES; HEART; HUMANS; MONOCYTES; MYOCARDIAL INFARCTION;

EID: 84887470030     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3367     Document Type: Article

References (16)

1. Doody, R.S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350 (2013)
2. Fleisher, A.S. et al. Phase 2 safety trial targeting amyloid b production with a g-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038 (2008)
3. Portelius, E. et al. A novel Ab isoform pattern in CSF reflects g-secretase inhibition in Alzheimer's disease. Alzheimers Res. Ther. 2, 7 (2010)
4. Scheuner, D. et al. Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870 (1996)
5. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144 (2010)
6. Levitan, D. & Greenwald, I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377, 351-354 (1995)
7. Xia, X. et al. Loss of presenilin 1 is associated with enhanced b-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10863-10868 (2001)
8. van Es, J.H. et al. Notch/g-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005)
9. Wong, G.T. et al. Chronic treatment with the g-secretase inhibitor LY-411,575 inhibits b-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882 (2004)
10. Kuhn, P.H. et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 31, 3157-3168 (2012)
11. Willem, M. et al. Control of peripheral nerve myelination by the b-secretase BACE1. Science 314, 664-666 (2006)
12. Cheret, C. et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 32, 2015-2028 (2013)
13. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012)
14. Savva, G.M. et al. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302-2309 (2009)
15. Holmes, C. et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223 (2008)
16. Orgogozo, J.-M. et al. Subacute meningoencephalitis in a subset of patients with AD after Ab42 immunization. Neurology 61, 46-54 (2003)